SCHEMBL29387237

SCHEMBL29387237

CC(C)[C@H](N)C(=O)C(=O)OCc1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC15A1 P46059 1/20 0.57
ALDH1A1 P00352 4/20 0.51
SLC1A3 P43003 2/20 0.47
SLC1A2 P43004 2/20 0.47
SLC1A1 P43005 2/20 0.47
KMT2A Q03164 2/20 0.47
MEN1 O00255 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
MAPK1 P28482 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
SLC6A2 P23975 1/20 0.46
SLC6A3 Q01959 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
LMNA P02545 2/20 0.43
ELANE P08246 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
LTA4H P09960 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15514249 1.00 SLC15A1 (0.57) SLC15A1ALDH1A1SLC1A3SLC1A2SLC1A1
SCHEMBL29819498 0.89 ALDH1A1 (0.50) SLC15A1ALDH1A1SLC1A3SLC1A2SLC1A1
SCHEMBL8716286 0.88 ALDH1A1 (0.49) SLC15A1ALDH1A1SLC1A3SLC1A2SLC1A1
SCHEMBL29772314 0.87 ALDH1A1 (0.55) SLC15A1ALDH1A1SLC1A3SLC1A2SLC1A1
SCHEMBL8882746 0.86 ALDH1A1 (0.47) SLC15A1ALDH1A1SLC1A3SLC1A2SLC1A1
SCHEMBL542444 0.85 SLC15A1 (0.61) SLC15A1ALDH1A1SLC1A3SLC1A2SLC1A1
SCHEMBL354949 0.85 SLC15A1 (0.61) SLC15A1ALDH1A1SLC1A3SLC1A2SLC1A1
SCHEMBL2137609 0.85 SLC15A1 (0.61) SLC15A1ALDH1A1SLC1A3SLC1A2SLC1A1
Hydrochloric Acid SCHEMBL2135391 0.83 SLC15A1 (0.59) SLC15A1ALDH1A1SLC1A3SLC1A2SLC1A1
Hydrochloric Acid SCHEMBL2137602 0.83 SLC15A1 (0.59) SLC15A1ALDH1A1SLC1A3SLC1A2SLC1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114144159-B Nanoparticles comprising dead sea extracts and uses thereof AHAVA-死海实验室有限公司 2024-10-01 CN claimed
US-20220183938-A1 NANOPARTICLES COMPRISING DEAD SEA EXTRACT AND USES THEREOF AHAVA - DEAD SEA LABORATORIES LTD. (IL) 2022-06-16 US claimed
CN-114144159-A Nanoparticles comprising dead sea extract and uses thereof AHAVA-死海实验室有限公司 2022-03-04 CN claimed
EP-3952826-A1 NANOPARTICLES COMPRISING DEAD SEA EXTRACT AND USES THEREOF AHAVA - DEAD SEA LABORATORIES LTD. (IL) 2022-02-16 EP claimed
US-20260144674-A1 Apparatus and Methods for Drug Delivery Using Microneedles CLEARSIDE BIOMEDICAL, INC. (US) 2026-05-28 US disclosed
US-20250345206-A1 APPARATUS AND METHODS FOR OCULAR INJECTION CLEARSIDE BIOMEDICAL, INC. (US) 2025-11-13 US disclosed
US-12350261-B2 Methods and devices for the treatment of ocular diseases in human subjects CLEARSIDE BIOMEDICAL, INC. (US) 2025-07-08 US disclosed
US-20250186253-A1 DEVICES AND METHODS FOR ADJUSTING THE INSERTION DEPTH OF A NEEDLE FOR MEDICAMENT DELIVERY CLEARSIDE BIOMEDICAL, INC. (US) 2025-06-12 US disclosed
EP-4566672-A2 METHODS FOR THE TREATMENT OF OCULAR DISEASE IN HUMAN SUBJECTS Clearside Biomedical Inc. (US) 2025-06-11 EP disclosed
EP-3554435-B1 SYSTEMS FOR DELIVERING DRUGS TO RETINAL TISSUE CLEARSIDE BIOMEDICAL INC (US) 2025-06-04 EP disclosed
US-20250152413-A1 SYSTEMS, DEVICES, AND METHODS FOR NEEDLE-LESS OCULAR INJECTIONS CLEARSIDE BIOMEDICAL INC (US) 2025-05-15 US disclosed
EP-3721872-B1 METHODS FOR THE TREATMENT OF OCULAR DISEASE IN HUMAN SUBJECTS CLEARSIDE BIOMEDICAL INC (US) 2025-01-22 EP disclosed
EP-2887982-B1 APPARATUS FOR DRUG DELIVERY USING MICRONEEDLES CLEARSIDE BIOMEDICAL INC (US) 2022-11-23 EP disclosed
US-11504431-B2 Formulations for the suprachoroidal space of an eye and methods EMORY UNIVERSITY (US) 2022-11-22 US disclosed
US-20220280341-A1 APPARATUS AND METHODS FOR DRUG DELIVERY USING MICRONEEDLES CLEARSIDE ROYALTY LLC 2022-09-08 US disclosed
US-20220280386-A1 METHODS AND APPARATUS FOR EXTRACTING FLUID FROM CONTAINER CLEARSIDE BIOMEDICAL, INC. 2022-09-08 US disclosed
US-20220183938-A1 NANOPARTICLES COMPRISING DEAD SEA EXTRACT AND USES THEREOF AHAVA - DEAD SEA LABORATORIES LTD. (IL) 2022-06-16 US disclosed
WO-2022076938-A1 APPARATUS AND METHODS OF RETINAL INJECTION CLEARSIDE BIOMEDICAL, INC. (US) 2022-04-14 WO disclosed
CN-114144159-A Nanoparticles comprising dead sea extract and uses thereof AHAVA-死海实验室有限公司 2022-03-04 CN disclosed
EP-3952826-A1 NANOPARTICLES COMPRISING DEAD SEA EXTRACT AND USES THEREOF AHAVA - DEAD SEA LABORATORIES LTD. (IL) 2022-02-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260144674-A1 Apparatus and Methods for Drug Delivery Using Microneedles PROKR2, SLC10A2, GLP1R SLC15A1 315/4885ALDH1A1 4190/4885SLC1A3 290/4885
US-20220183938-A1 NANOPARTICLES COMPRISING DEAD SEA EXTRACT AND USES THEREOF CUTA, DSG1, CD63 SLC15A1 3114/4885ALDH1A1 3761/4885SLC1A3 4428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.